ESR1 and breast carcinoma: In ER-positive breast cancer cells, endocrine therapy resistance often occurs through the enhancement of estrogen signaling, which can be brought on by factors such as ERα overexpression/amplification, acquired gain-of-function mutations of ERα, and altered interactions between ERα and coregulators [24].